

Autologous Serum Tears

Table of Content

<u>Purpose</u>

Description & Definitions

<u>Criteria</u> Coding

Document History

References

Special Notes

Keywords

Effective Date 09/2007

Next Review Date 9/2024

Coverage Policy Medical 244

<u>Version</u> 4

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details*.

Purpose:

This policy addresses the medical necessity of Autologous Serum Tears.

Description & Definitions:

Autologous serum tears use an individual's own blood for the preparation and production of serum for dry eyes.

Criteria:

Autologous Serum Tears are considered medically necessary for ALL of the following:

- Individual has Sjogrens disease.
- Individual has failed other treatments.

Autologous Serum Tears are considered not medically necessary for any use other than those indicated in clinical criteria.

Coding:

Medically necessary with criteria:

Coding	Description
92499	Unlisted ophthalmological service or procedure.

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Medical 244 Page 1 of 3

Revised Dates:

- 2020: January
- 2015: March
- 2013: August
- 2012: August
- 2011: September
- 2010: December
- 2009: November

Reviewed Dates:

- 2023: September
- 2022: September
- 2021: December
- 2020: December
- 2019: December
- 2018: October
- 2017: November
- 2016: August
- 2015: August
- 2014: August
- 2010: August, November
- 2009: August
- 2008: August

Effective Date:

• September 2007

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Retrieved Aug 30, 2023, from Hayes, Inc:

https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522autologous%2520Serum%2520Tears%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%257B%2522page%2522:0,%2522size%2522:50%257D,%2522type%2522:%2522all%2522,%252

(2023). Retrieved Aug 30, 2023, from Centers for Medicare and Medicaid Services:

https://www.cms.gov/medicare-coverage-database/search-

results.aspx?keyword=Tears&keywordType=starts&areald=s53&docType=NCA,CAL,NCD,MEDCAC,TA,MCD,6,3,5,1,F,P&contractOption=all&sortBy=relevance

(2023). Retrieved Aug 30, 2023, from Carelon Medical Benefits Management:

https://guidelines.carelonmedicalbenefitsmanagement.com/?s=Autologous+serum+tears&et_pb_searchform_submit=et_search_proccess&et_pb_search_cat=11%2C1%2C96&et_pb_include_posts=yes

(2023, Jun 27). Retrieved Aug 30, 2023, from MCG: https://careweb.careguidelines.com/ed27/index.html

(2023). Retrieved Aug 30, 2023, from Department of Medical Assistance Services:

https://vamedicaid.dmas.virginia.gov/manuals/provider-manuals-

library#gsc.tab=0&gsc.q=autologous%20serum%20tears&gsc.sort=

Medical 244 Page 2 of 3

Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease OTA. (2019, Aug). Retrieved Aug 30, 2023, from American Academy of Ophthalmology: https://www.aao.org/education/ophthalmic-technology-assessment/autologous-serum-based-eye-drops-treatment-of-ocul

Baer, A., & Akpek, E. (2022, Mar 07). Treatment of moderate to severe dry eye in Sjögren's disease. Retrieved Aug 30, 2023, from UpToDate: https://www.uptodate.com/contents/treatment-of-moderate-to-severe-dry-eye-in-sjogrens-

disease?search=autologous%20serum%20tears%5D&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H1638685620

Bedinghaus, T. (2023, May 23). Will Autologous Serum Eye Drops Work for Me? Retrieved Aug 30, 2023, from Very Well Health: https://www.verywellhealth.com/autologous-serum-eye-drops-3422030

Guidance, Compliance & Regulatory Information (Biologics). (2022, Dec 14). Retrieved Aug 30, 2023, from U.S. Food and Drug Administration: https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics

Special Notes: *

This medical policy expresses Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Keywords:

Autologous Serum Tears, SHP Prolotherapy, Medical 108, SHP Medical 244, Sjogren's Disease, dry eyes, Autologous serum eye drops, ASED, Biological tear

Medical 244 Page 3 of 3